Detalhe da pesquisa
1.
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
Mod Pathol
; 37(4): 100445, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341130
2.
Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
Gynecol Oncol
; 184: 67-73, 2024 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38290412
3.
The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing.
Genes Chromosomes Cancer
; 62(10): 589-596, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222498
4.
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 24(2): 162-174, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36623515
5.
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Breast Cancer Res Treat
; 202(1): 191-201, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589839
6.
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Oncologist
; 27(3): 167-174, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274707
7.
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Mod Pathol
; 34(6): 1185-1193, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462368
8.
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
Gynecol Oncol
; 163(3): 563-568, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34742578
9.
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
Gynecol Oncol
; 160(3): 777-785, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563487
10.
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Br J Cancer
; 119(9): 1060-1066, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30318511
11.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Br J Cancer
; 119(11): 1401-1409, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30353044
12.
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Breast Cancer Res Treat
; 168(3): 625-630, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29275435
13.
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
Invest New Drugs
; 36(5): 828-835, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29313279
14.
AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.
Hum Mol Genet
; 24(18): 5093-108, 2015 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26085575
15.
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Breast Cancer Res Treat
; 151(3): 629-38, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26006067
16.
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Breast Cancer Res
; 16(6): 475, 2014 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25475740
17.
Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
Eur Urol Oncol
; 7(3): 597-604, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38182487
18.
Mapping of homozygous deletions in verified esophageal adenocarcinoma cell lines and xenografts.
Genes Chromosomes Cancer
; 51(3): 272-82, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22081516
19.
Association of Genomic Instability Score, Tumor Mutational Burden, and Tumor-Infiltrating Lymphocytes as Biomarkers in Uterine Serous Carcinoma.
Cancers (Basel)
; 15(2)2023 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36672477
20.
BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Gynecol Oncol
; 125(3): 677-82, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22406760